Morgan Stanley remains cautious on Hims & Hers Health, Inc. (NYSE: HIMS) despite the company’s latest move into at-home lab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE